Drug Profile
MET 409
Alternative Names: MET-409Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Metacrine
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- No development reported Inflammatory bowel diseases; Irritable bowel syndrome
Most Recent Events
- 01 Sep 2023 Chemical structure information added
- 02 Nov 2021 Efficacy and adverse events data from a phase IIa trial in Non-alcoholic steatohepatitis released by Metacrine
- 28 Jul 2021 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in Netherlands (PO)